89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Tr

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session T

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session T
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , San Francisco , California , Hank Mansbach , Deepakl Bhatt , Bryan Martins , Linkedin , Icahn School Of Medicine At Mount Sinai , Pj Kelleherlifesci Advisors , American College Of Cardiology , World Congress , Nasdaq , American College , Annual Scientific Session , Expo Together , Mount Sinai Heart , Valentin Fuster Professor , Cardiovascular Medicine , Icahn School , Mount Sinai , Chief Medical Officer , Percent Change , Wilcoxon Rank Sum , Overall Population , Pegozafermin Treated Population , Background Therapy , Treated Patients , Statements Certain , Quarterly Report , Safe Harbor , Private Securities Litigation Reform Act , Ryan Martins Chief Financial Officer , Lifesci Advisors , Sheryl Seapy Real Chemistry ,